
TY  - JOUR
TI  - Oral Abstracts
JO  - Mycoses
VL  - 55
IS  - s4
SN  - 0933-7407
UR  - https://doi.org/10.1111/j.1439-0507.2012.02205.x
DO  - doi:10.1111/j.1439-0507.2012.02205.x
SP  - 57
EP  - 94
PY  - 2012
ER  - 

TY  - JOUR
TI  - SIOP 2013 Scientific Programme + Index
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 60
IS  - S3
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.24719
DO  - doi:10.1002/pbc.24719
SP  - S1
EP  - S264
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Asia-Pacific Journal of Clinical Oncology
JA  - Asia‐Pac J Clin Oncol
VL  - 10
IS  - S9
SN  - 1743-7555
UR  - https://doi.org/10.1111/ajco.12332
DO  - doi:10.1111/ajco.12332
SP  - 1
EP  - 264
PY  - 2014
ER  - 

TY  - JOUR
TI  - 2013 Meeting of the Peripheral Nerve Society, June 29–July 3, 2013, Saint–Malo, France
JO  - Journal of the Peripheral Nervous System
JA  - J Peripher Nerv Syst
VL  - 18
IS  - s2
SN  - 1085-9489
UR  - https://doi.org/10.1111/jns5.12025
DO  - doi:10.1111/jns5.12025
SP  - 1
EP  - 131
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts 1 to 257
JO  - Hepatology
JA  - Hepatology
VL  - 42
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.20923
DO  - doi:10.1002/hep.20923
SP  - 196A
EP  - 298A
PY  - 2005
ER  - 

TY  - JOUR
TI  - POSTER SESSIONS
JO  - Allergy
VL  - 63
IS  - s88
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2008.01760.x
DO  - doi:10.1111/j.1398-9995.2008.01760.x
SP  - 158
EP  - 611
PY  - 2008
ER  - 

TY  - JOUR
TI  - 49th ANNUAL MEETING
JO  - Medical Physics
JA  - Med. Phys.
VL  - 34
IS  - 6Part24
SN  - 0094-2405
UR  - https://doi.org/10.1002/j.2473-4209.2007.tb00534.x
DO  - doi:10.1002/j.2473-4209.2007.tb00534.x
SP  - 2261
EP  - 2672
PY  - 2007
ER  - 

AU  - Handler, Norbert
C7  - pp. 275-312
TI  - Pharmacophore Generation for Multiple Ligands
SN  - 9783527335381
UR  - https://doi.org/10.1002/9783527674381.ch10
DO  - doi:10.1002/9783527674381.ch10
SP  - 275-312
KW  - dual inhibitors
KW  - kinase inhibitors
KW  - ligand-based pharmacophore modeling
KW  - multiple ligands
KW  - pharmacophore generation
KW  - structure-based pharmacophore modeling
KW  - virtual screening
PY  - 2007
AB  - Summary In principle, for the development of pharmacophore models, two different approaches are known, the ligand-based and the structure-based approaches. Ligand-based pharmacophore modeling is an important tool for facilitating drug discovery in the absence of a macromolecular target structure. Structure-based pharmacophore modeling is based on the 3D structure of a macromolecule-ligand complex or a macromolecule without a ligand. As every virtual screening tool, also pharmacophore modeling very much depends on the data employed for model generation, refinement, and theoretical validation. This chapter describes the entire multiple ligand continuum from linked pharmacophore patterns to highly integrated examples including biological results to illustrate the broad spectrum of successful pathways for design and development of multiple ligands. It discusses the author's work to develop efficient kinase inhibitors to enable the development and characterization of further kinase targets and drugs.
ER  - 

TY  - JOUR
TI  - ACCP Virtual Poster Symposium
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 37
IS  - 6
SN  - 9783527335381
UR  - https://doi.org/10.1002/phar.1964
DO  - doi:10.1002/phar.1964
SP  - e38
EP  - e70
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 72
IS  - S4
SN  - 9783527335381
UR  - https://doi.org/10.1111/anae.14060
DO  - doi:10.1111/anae.14060
SP  - 10
EP  - 88
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Psychophysiology
JA  - Psychophysiol
VL  - 50
IS  - S1
SN  - 9783527335381
UR  - https://doi.org/10.1111/psyp.12120
DO  - doi:10.1111/psyp.12120
SP  - S23
EP  - S136
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 10
IS  - s1
SN  - 9783527335381
UR  - https://doi.org/10.1111/j.1778-428X.2008.00098.x
DO  - doi:10.1111/j.1778-428X.2008.00098.x
SP  - 20
EP  - 50
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts (Continue in Part XI)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1998
IS  - S1
SN  - 9783527335381
UR  - https://doi.org/10.1002/mrmp.22419980111
DO  - doi:10.1002/mrmp.22419980111
SP  - 501
EP  - 550
PY  - 1998
ER  - 

TY  - JOUR
TI  - 2006 Abstracts: Twenty-Eighth Annual Meeting of the American Society for Bone and Mineral Research: Pennsylvania Convention Convention Center Philadelphia, Pennsylvania, USA, September 15–19, 2006
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 21
IS  - S1
SN  - 9783527335381
UR  - https://doi.org/10.1002/jbmr.5650211402
DO  - doi:10.1002/jbmr.5650211402
SP  - S2
EP  - S51
PY  - 2006
ER  - 

TY  - JOUR
AU  - Bricker, Harvey M.
AU  - Mellars, Paul
AU  - Peterkin, Gail Larsen
TI  - Introduction: The Study of Palaeolithic and Mesolithic Hunting
JO  - Archaeological Papers of the American Anthropological Association
VL  - 4
IS  - 1
SN  - 9783527335381
UR  - https://doi.org/10.1525/ap3a.1993.4.1.1
DO  - doi:10.1525/ap3a.1993.4.1.1
SP  - 1
EP  - 9
PY  - 1993
ER  - 

TY  - JOUR
TI  - American Epilepsy Society Proceedings
JO  - Epilepsia
VL  - 36
IS  - s4
SN  - 9783527335381
UR  - https://doi.org/10.1111/j.1528-1157.1995.tb01720.x
DO  - doi:10.1111/j.1528-1157.1995.tb01720.x
SP  - S1
EP  - S172
PY  - 1995
ER  - 

TY  - JOUR
TI  - Invited Presentations
JO  - Nephrology
VL  - 3
IS  - S1
SN  - 9783527335381
UR  - https://doi.org/10.1111/j.1440-1797.1997.tb00554.x
DO  - doi:10.1111/j.1440-1797.1997.tb00554.x
SP  - S1
EP  - S630
PY  - 1997
ER  - 

TY  - JOUR
TI  - 2015 Peripheral Nerve Society Biennial Meeting
JO  - Journal of the Peripheral Nervous System
JA  - J Peripher Nerv Syst
VL  - 20
IS  - 2
SN  - 9783527335381
UR  - https://doi.org/10.1111/jns.12129
DO  - doi:10.1111/jns.12129
SP  - 88
EP  - 253
PY  - 2015
ER  - 

TY  - JOUR
TI  - Wednesday July 5, 2006 17:30–19:00 Hall 1 Schwarz Pharma & Valeant Pharmaceuticals International Satellite Symposium What's around the corner: AEDs in late development
JO  - Epilepsia
VL  - 47
IS  - s3
SN  - 9783527335381
UR  - https://doi.org/10.1111/j.1528-1167.2006.00715_90.x
DO  - doi:10.1111/j.1528-1167.2006.00715_90.x
SP  - 272
EP  - 272
PY  - 2006
AB  - 1 E. Ben-Menachem ( 1 Neurologkliniken, Sahlgrenska Universitetssjukhuset, Goteberg, Sweden ) Lacosamide is in Phase 3 of clinical development for the adjunctive treatment of epilepsy and neuropathic pain. Currently the mode of action (MOA) is under investigation since it has been previously demonstrated that lacosamide does not share a MOA with other currently marketed antiepileptic drugs (AEDs). The drug can be administered orally or intravenously. Results from pharmacokinetic studies suggest that lacosamide has a low potential for drug-drug interactions, and it appears that lacosamide has a minimal risk for affecting the pharmacokinetics of commonly prescribed concomitant AEDs for the treatment of epilepsy. In a double-blind, randomized, placebo-controlled, multicenter trial for the treatment of partial seizures (SP667), lacosamide was administered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily doses. In this trial, lacosamide demonstrated a statistically significant reduction in seizure frequency over placebo. Moreover, the 50% responder rate (defined as patients with at least a 50% reduction in seizure frequency) was statistically significant. A further trial (SP616) investigated the safety, tolerability and pharmacokinetics of IV lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. The nature of AEs reported following 60- and 30 minute infusions of lacosamide was consistent with AEs reported following oral administration of lacosamide. Dose-related adverse events include dizziness, nausea, fatigue, ataxia, vision abnormal, diplopia, and nystagmus. The currently available results justify the further development of lacosamide for the treatment of epilepsy.
ER  - 

AU  - Rodger, Marc A.
AU  - Le Templier, Genevieve
C7  - pp. 111-152
TI  - Anticoagulant Therapy During Pregnancy and Gynecology
SN  - 9781405183994
UR  - https://doi.org/10.1002/9781444328332.ch6
DO  - doi:10.1002/9781444328332.ch6
SP  - 111-152
KW  - heparin
KW  - warfarin
KW  - venous thromboembolism
KW  - pulmonary embolism
KW  - d dimer
KW  - venography
KW  - thrombophilia
KW  - pregnancy
KW  - malignancy
KW  - heparin induced thrombocytopenia
PY  - 2006
AB  - Summary Anticoagulant therapy in obstetrics and gynecology is required in the management of venous thromboembolism, in women with mechanical heart valve replacement, thrombophilia, after prolonged surgeries and malignancies. Without anticoagulation therapy, these conditions carry a high morbidity and mortality. Management includes early mobilization, graduated compression stockings low dose heparin and intermittent pneumatic compression pumps. The most effective tools are thromboprophylaxis with low molecular weight heparin, warfarin or fondaparinux. The later agents are associated with higher risk of bleeding, cost and more laboratory monitoring. This chapter gives an overview of anticoagulant therapy in obstetrics and gynecology.
ER  - 
